PubRank

Giuseppe Giaccone

Author PubWeight™ 276.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003 15.10
2 Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010 8.56
3 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004 8.15
4 Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010 6.81
5 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009 4.95
6 Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007 4.40
7 Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005 4.04
8 Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013 4.04
9 Cell death independent of caspases: a review. Clin Cancer Res 2005 3.85
10 American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011 3.73
11 Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013 3.71
12 Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009 3.65
13 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2011 3.21
14 Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003 2.95
15 Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013 2.71
16 Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013 2.66
17 Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol 2003 2.62
18 Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002 2.55
19 Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008 2.51
20 Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003 2.44
21 Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006 2.33
22 Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012 2.26
23 Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002 2.18
24 Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005 2.15
25 An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009 2.03
26 Apoptosis: target of cancer therapy. Clin Cancer Res 2002 1.99
27 Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A 2012 1.97
28 Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010 1.96
29 MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010 1.89
30 Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002 1.72
31 Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2008 1.70
32 Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006 1.67
33 Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007 1.60
34 Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 2010 1.56
35 Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol 2014 1.56
36 Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol 2002 1.52
37 Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol 2006 1.52
38 EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol 2007 1.48
39 Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A 2010 1.45
40 Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 2008 1.44
41 CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 2002 1.44
42 Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2006 1.43
43 How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging 2006 1.41
44 Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer 2007 1.38
45 Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008 1.37
46 Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008 1.36
47 Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 2009 1.36
48 Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008 1.36
49 TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007 1.34
50 Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 2004 1.34
51 Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 2006 1.33
52 Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell 2006 1.33
53 Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005 1.32
54 A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006 1.30
55 Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol 2005 1.30
56 Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 2006 1.28
57 STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 2010 1.27
58 Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011 1.25
59 A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012 1.23
60 Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010 1.23
61 Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2007 1.21
62 Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 2012 1.21
63 The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014 1.21
64 Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 2011 1.20
65 Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 2009 1.20
66 A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011 1.20
67 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 2011 1.16
68 Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 2011 1.16
69 A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 2014 1.15
70 Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol 2010 1.15
71 Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008 1.14
72 The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014 1.12
73 A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010 1.12
74 Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther 2007 1.11
75 Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics Clin Appl 2007 1.10
76 Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 2002 1.08
77 Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. Exp Cell Res 2004 1.08
78 EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 2011 1.07
79 The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 2004 1.06
80 Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol 2005 1.05
81 Treatment of advanced thymoma and thymic carcinoma. Curr Treat Options Oncol 2009 1.04
82 Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010 1.04
83 Homodimerization antagonizes nuclear export of survivin. Traffic 2007 1.04
84 Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer 2005 1.03
85 The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. J Thorac Oncol 2013 1.00
86 Biology and management of malignant pleural mesothelioma. Eur J Cancer 2006 1.00
87 The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 2006 1.00
88 MicroRNA expression and clinical outcome of small cell lung cancer. PLoS One 2011 0.99
89 Targeted agents: how to select the winners in preclinical and early clinical studies? Eur J Cancer 2011 0.99
90 Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res 2003 0.99
91 EGFR inhibitors in lung cancer. Oncology (Williston Park) 2005 0.98
92 Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol 2014 0.98
93 The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014 0.98
94 Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J Clin Oncol 2010 0.96
95 Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med (Berl) 2014 0.96
96 Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res 2011 0.96
97 Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A 2012 0.96
98 Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years. J Clin Endocrinol Metab 2012 0.95
99 Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur J Pharmacol 2010 0.95
100 Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des 2007 0.95
101 Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 2011 0.95
102 A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 2007 0.95
103 CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. J Clin Invest 2014 0.95
104 The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Curr Opin Investig Drugs 2009 0.95
105 Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol 2006 0.95
106 Small-molecule inhibitors of the human epidermal receptor family. Expert Opin Investig Drugs 2009 0.94
107 Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med 2009 0.93
108 Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010 0.93
109 Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer 2010 0.93
110 The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene 2004 0.93
111 Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009 0.93
112 A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer 2010 0.93
113 A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anticancer Drugs 2007 0.92
114 Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. Mol Cancer Ther 2013 0.91
115 HER2 mutations in non-small-cell lung cancer can be continually targeted. J Clin Oncol 2012 0.90
116 Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. Curr Opin Oncol 2012 0.90
117 Characterization and management of cardiac involvement of thymic epithelial tumors. J Thorac Oncol 2013 0.90
118 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 2010 0.90
119 Drug development: portals of discovery. Clin Cancer Res 2012 0.90
120 Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain. Mol Cancer 2007 0.90
121 Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002 0.89
122 The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo. Clin Cancer Res 2013 0.89
123 Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res 2004 0.89
124 Acupuncture treatment for persistent hiccups in patients with cancer. J Altern Complement Med 2010 0.89
125 Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer 2009 0.89
126 Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. Clin Cancer Res 2011 0.89
127 Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front Oncol 2013 0.89
128 Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Curr Opin Oncol 2005 0.89
129 Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res 2004 0.88
130 Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer 2010 0.88
131 Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. Hum Mol Genet 2005 0.88
132 Chemotherapy for thymic tumors: induction, consolidation, palliation. Thorac Surg Clin 2011 0.87
133 Targeted therapy for advanced thymic tumors. J Thorac Oncol 2010 0.87
134 Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn 2010 0.87
135 Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. Exp Cell Res 2006 0.87
136 Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002 0.86
137 Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 2011 0.86
138 Comparative proteomics analysis of caspase-9-protein complexes in untreated and cytochrome c/dATP stimulated lysates of NSCLC cells. J Proteomics 2008 0.86
139 The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer 2007 0.85
140 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. Clin Cancer Res 2013 0.84
141 Emerging protein kinase inhibitors for non-small cell lung cancer. Expert Opin Emerg Drugs 2013 0.84
142 Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2003 0.84
143 Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res 2005 0.84
144 Image microarrays (IMA): Digital pathology's missing tool. J Pathol Inform 2011 0.84
145 Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. J Thorac Oncol 2014 0.84
146 Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. Clin Cancer Res 2013 0.84
147 Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three cases. J Thorac Oncol 2007 0.83
148 FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy. Clin Lung Cancer 2005 0.83
149 Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2013 0.83
150 Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. J Clin Oncol 2012 0.83
151 [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. Zhongguo Fei Ai Za Zhi 2010 0.82
152 Lung cancer vaccines. Cancer J 2011 0.82
153 Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst 2013 0.82
154 Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets 2010 0.82
155 Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin Cancer Res 2011 0.82
156 Genotype analysis of the VNTR polymorphism in the SMYD3 histone methyltransferase gene: lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC. Int J Cancer 2008 0.81
157 A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer 2005 0.81
158 Whole genome and transcriptome sequencing of a B3 thymoma. PLoS One 2013 0.81
159 Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer. J Thorac Oncol 2014 0.81
160 Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells. Cancer Res 2002 0.81
161 The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer 2002 0.81
162 A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res 2007 0.81
163 The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol 2014 0.80
164 Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2013 0.80
165 Tyrosine kinase inhibitors in lung cancer. Hematol Oncol Clin North Am 2012 0.80
166 Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. Cancer Gene Ther 2004 0.80
167 Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples. Acta Cytol 2012 0.80
168 International thymic malignancy interest group. J Thorac Oncol 2010 0.80
169 Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma. J Thorac Oncol 2013 0.80
170 Thymoma-associated paraneoplastic polymyositis. J Clin Oncol 2010 0.79
171 Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins. Biochem J 2003 0.79
172 Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. J Thorac Oncol 2011 0.79
173 Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. Int J Oncol 2010 0.79
174 Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010 0.79
175 Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci 2013 0.79
176 Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. Immunotherapy 2011 0.79
177 TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells. BMC Cancer 2006 0.79
178 Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. Oncologist 2013 0.79
179 Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. Exp Cell Res 2003 0.79
180 Population pharmacokinetics of the novel anticancer agent KRN7000. Cancer Chemother Pharmacol 2002 0.79
181 DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. Curr Drug Metab 2011 0.78
182 Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer 2008 0.78
183 Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology. Clin Lung Cancer 2006 0.78
184 Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. Clin Lung Cancer 2013 0.78
185 NUT rearrangement is uncommon in human thymic epithelial tumors. J Thorac Oncol 2012 0.78
186 Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res 2006 0.78
187 The expression of TUCAN, an inhibitor of apoptosis protein, in patients with advanced non-small cell lung cancer treated with chemotherapy. Anticancer Res 2006 0.77
188 18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer. J Natl Cancer Inst 2007 0.77
189 Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer 2003 0.77
190 Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement. J Thorac Oncol 2012 0.77
191 Natural Killer T cells. Lancet Oncol 2002 0.77
192 Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. Nat Rev Clin Oncol 2010 0.77
193 Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Mol Cancer Ther 2009 0.76
194 "Pseudocavitation" in thymic carcinoma during treatment with sunitinib. J Thorac Oncol 2013 0.76
195 The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 2004 0.76
196 The role of talactoferrin alpha in the treatment of non-small cell lung cancer. Expert Opin Biol Ther 2010 0.76
197 Challenges in cancer molecular targets and therapeutics. Front Oncol 2011 0.75
198 Signal transduction modulators for cancer therapy: from promise to practice? Oncologist 2003 0.75
199 Multiorgan autoimmune manifestations associated with thymoma. J Thorac Oncol 2015 0.75
200 Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report. Cases J 2009 0.75
201 The role of EGFR-TK inhibition in non-small cell lung cancer. Onkologie 2005 0.75
202 Keynote comment: are large-scale cancer-genomics projects ready to use? Lancet Oncol 2006 0.75
203 Antiangiogenic therapy in nonsmall cell lung cancer. Curr Opin Oncol 2008 0.75
204 Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. Eur J Cancer 2006 0.75
205 Thymomas: the need for prospective studies. J Thorac Oncol 2013 0.75
206 Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. Clin Cancer Res 2008 0.75
207 Antiangiogenesis induced tumor cavitation in lung cancer. J Thorac Oncol 2009 0.75